Disclaimer: This article has been developed and funded by Daiichi Sankyo. Daiichi Sankyo has more than 120 years of experience and scientific expertise. In 2019, they entered the oncology market ...

Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced non ...

At the annual National Cherry Blossom Festival this year, which wrapped up this past weekend, Japanese drugmaker Daiichi Sankyo went back to visit the roots it planted in the nation’s capital ...

Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the DESTINY-Gastric04 Phase III trial, regarding the primary endpoint of ...

Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY – Get Free Report) was the target of a significant growth in short interest in March.As of March 31st, there was short interest totalling 184,100 ...